دورية أكاديمية
Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies.
| العنوان: | Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies. |
|---|---|
| المؤلفون: | Dannenfelser R; Department of Computer Science, Princeton University, Princeton, NJ 08540, USA; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544, USA., Allen GM; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA; Cell Design Institute and Center for Synthetic Immunology, University of California, San Francisco, San Francisco, CA 94158, USA., VanderSluis B; Center for Computational Biology, Flatiron Institute, New York, NY 10010, USA., Koegel AK; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA; Cell Design Institute and Center for Synthetic Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; Division of Pediatric Oncology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94158, USA., Levinson S; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA., Stark SR; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA; Cell Design Institute and Center for Synthetic Immunology, University of California, San Francisco, San Francisco, CA 94158, USA., Yao V; Department of Computer Science, Princeton University, Princeton, NJ 08540, USA; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544, USA; Department of Computer Science, Rice University, Houston, TX 77005, USA., Tadych A; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544, USA., Troyanskaya OG; Department of Computer Science, Princeton University, Princeton, NJ 08540, USA; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544, USA; Center for Computational Biology, Flatiron Institute, New York, NY 10010, USA. Electronic address: ogt@genomics.princeton.edu., Lim WA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA; Cell Design Institute and Center for Synthetic Immunology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: wendell.lim@ucsf.edu. |
| المصدر: | Cell systems [Cell Syst] 2020 Sep 23; Vol. 11 (3), pp. 215-228.e5. Date of Electronic Publication: 2020 Sep 10. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 101656080 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-4720 (Electronic) Linking ISSN: 24054712 NLM ISO Abbreviation: Cell Syst Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Cambridge, MA] : Cell Press, [2015]- |
| مواضيع طبية MeSH: | Antigens, Neoplasm/*metabolism , Immunotherapy, Adoptive/*methods, Humans |
| مستخلص: | Precise discrimination of tumor from normal tissues remains a major roadblock for therapeutic efficacy of chimeric antigen receptor (CAR) T cells. Here, we perform a comprehensive in silico screen to identify multi-antigen signatures that improve tumor discrimination by CAR T cells engineered to integrate multiple antigen inputs via Boolean logic, e.g., AND and NOT. We screen >2.5 million dual antigens and ∼60 million triple antigens across 33 tumor types and 34 normal tissues. We find that dual antigens significantly outperform the best single clinically investigated CAR targets and confirm key predictions experimentally. Further, we identify antigen triplets that are predicted to show close to ideal tumor-versus-normal tissue discrimination for several tumor types. This work demonstrates the potential of 2- to 3-antigen Boolean logic gates for improving tumor discrimination by CAR T cell therapies. Our predictions are available on an interactive web server resource (antigen.princeton.edu). Competing Interests: Declaration of Interests W.A.L. is on the Scientific Advisory Board for Allogene Therapeutics and O.G.T. is on the Scientific Advisory Board for Caris Life Sciences. W.A.L. and O.G.T. have filed patents related to this work. (Copyright © 2020. Published by Elsevier Inc.) |
| التعليقات: | Comment in: Cell Syst. 2020 Nov 18;11(5):421-423. (PMID: 33212015) |
| References: | N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370) Mol Ther. 2013 Nov;21(11):2087-101. (PMID: 23939024) Cell Death Discov. 2019 May 1;5:91. (PMID: 31069116) Cell. 2016 Feb 11;164(4):780-91. (PMID: 26830878) Clin Cancer Res. 2017 May 1;23(9):2267-2276. (PMID: 27803044) Mol Ther. 2010 Apr;18(4):843-51. (PMID: 20179677) Hum Pathol. 2012 Sep;43(9):1394-9. (PMID: 22401771) J Immunol. 2003 Jan 1;170(1):33-40. (PMID: 12496380) Sci Transl Med. 2013 Dec 11;5(215):215ra172. (PMID: 24337479) Mol Cancer. 2019 Nov 4;18(1):153. (PMID: 31684958) Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. (PMID: 28660319) Science. 2015 Apr 3;348(6230):62-8. (PMID: 25838374) Cancer Res. 1997 Jul 1;57(13):2741-8. (PMID: 9205085) Cancer Cell. 2019 Mar 18;35(3):489-503.e8. (PMID: 30889382) Cell Syst. 2019 Jun 26;8(6):483-493.e7. (PMID: 31176620) Mol Ther Nucleic Acids. 2013 Jul 09;2:e105. (PMID: 23839099) Biostatistics. 2007 Jan;8(1):118-27. (PMID: 16632515) Mol Ther. 2011 Mar;19(3):620-6. (PMID: 21157437) Oncol Lett. 2016 Dec;12(6):5085-5091. (PMID: 28105215) Database (Oxford). 2014 Feb 25;2014:bau012. (PMID: 24573882) J Cell Biol. 1998 Jun 15;141(6):1467-76. (PMID: 9628901) Cell. 2016 Oct 6;167(2):419-432.e16. (PMID: 27693353) Nature. 2017 Oct 11;550(7675):204-213. (PMID: 29022597) Oncotarget. 2016 Jul 5;7(27):41929-41947. (PMID: 27259239) Cell. 2016 Feb 11;164(4):770-9. (PMID: 26830879) Int Immunol. 1994 Mar;6(3):477-80. (PMID: 8186199) Nat Biotechnol. 2013 Jan;31(1):71-5. (PMID: 23242161) Mol Ther. 2013 Apr;21(4):904-12. (PMID: 23423337) J Clin Immunol. 2012 Oct;32(5):1059-70. (PMID: 22526592) N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797) Oncotarget. 2016 Apr 12;7(15):20440-54. (PMID: 26943033) Br J Cancer. 2015 Aug 11;113(4):616-25. (PMID: 26180925) J Cancer. 2020 Feb 21;11(10):2830-2844. (PMID: 32226501) |
| معلومات مُعتمدة: | R01 CA196277 United States CA NCI NIH HHS; R01 GM071966 United States GM NIGMS NIH HHS; T32 HG003284 United States HG NHGRI NIH HHS; U54 CA244438 United States CA NCI NIH HHS; United States HHMI Howard Hughes Medical Institute |
| فهرسة مساهمة: | Keywords: AND gate; CAR T cell; NOT gate; T cell therapeutics; combinatorial antigen recognition; tumor antigens; tumor-versus-normal discrimination |
| المشرفين على المادة: | 0 (Antigens, Neoplasm) |
| تواريخ الأحداث: | Date Created: 20200911 Date Completed: 20211001 Latest Revision: 20211001 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC7814417 |
| DOI: | 10.1016/j.cels.2020.08.002 |
| PMID: | 32916097 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2405-4720 |
|---|---|
| DOI: | 10.1016/j.cels.2020.08.002 |